Median Technologies to Participate in the 2024 ASCO Annual Meeting, May 31 - June 4, 2024, McCormick Place, Chicago, IL, USA
May 29 2024 - 10:45AM
Business Wire
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme
eligible, “Median” or “The Company”) announced today that the
Company will be participating in the 2024 American Society of
Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to
June 4, McCormick Place, Chicago, IL, USA. The Median team, with
iCRO and eyonis™ representatives will be pleased to welcome the
ASCO participants at booth #15142, South Building, Hall A,
McCormick place, from June 1 to 3 (exhibition dates), from 9:00 am
to 5:00 pm.
Median Technologies’ abstract selected for online publication is
available on the ASCO platform:
Abstract #e23010: Double reading
performance and the impact of adjudication on progression-free
survival estimations: Findings from a lung clinical trial The
FDA recommends Blinded Independent Central Review (BICR) with
double reads for imaging in clinical trials, but inter-reader
variability raises concerns. Our study examined this variability in
lung cancer clinical trials using RECIST. We analyzed 5 phase III
trials with 7 readers forming 11 teams, covering 1,017 patients.
The study focused on Discrepancy Rate (DR), bias, endorsement rate,
and the impact of adjudication on Progression-Free Survival (PFS)
estimates. Results showed significant bias among readers, affecting
double readings but no correlation between bias and DR.
Additionally, adjudication significantly affects PFS estimates.
These outcomes highlight the need to improve monitoring in clinical
trials.
The ASCO Annual Meeting is the world’s premier oncology
conference, organized by the American Society of Clinical Oncology,
the largest oncology society in the world. Each year, the ASCO
conference brings together more than 35,000 oncologists from all
around the globe, and is attended by all medical, educational and
industrial stakeholders involved in the field of oncology
worldwide. More about the ASCO Annual Meeting:
https://am.asco.org/
About Median Technologies: Pioneering in innovative imaging
solutions and services, Median Technologies harnesses cutting-edge
AI to elevate the accuracy of early cancer diagnoses and cancer
treatments. Median's offerings, including iCRO for medical image
analysis and management in oncology trials and eyonis™, AI/ML
tech-based suite of software as medical devices (SaMD), empower
biopharmaceutical entities and clinicians to advance patient care
and expedite novel therapies. The French-based company, with a
presence in the U.S. and China, trades on the Euronext Growth
market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for
the French SME equity savings plan scheme (PEA-PME). For more
information: www.mediantechnologies.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529187331/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ghislaine.gasparetto@seitosei-actifin.com
Median Technologies (EU:ALMDT)
Historical Stock Chart
From May 2024 to Jun 2024
Median Technologies (EU:ALMDT)
Historical Stock Chart
From Jun 2023 to Jun 2024